Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Mar;15(2):109-118.
doi: 10.2217/fca-2018-0009. Epub 2019 Jan 21.

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study

Luca D Esposti  1 , Jean-Baptiste Briere  2 , Kevin Bowrin  2 , Sangiorgi Diego  1 , Valentina Perrone  1 , Giuseppe Di Pasquale  3
Affiliations
Observational Study

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study

Luca D Esposti et al. Future Cardiol. 2019 Mar.

Abstract

Aim: To evaluate antithrombotic treatment patterns in patients in Italy with nonvalvular atrial fibrillation (NVAF) before and after direct oral anticoagulants (DOACs) were approved.

Methods: This analysis included patients with a discharge diagnosis of NVAF in 2010 and 2014, which constituted the pre- and post-DOACs populations, respectively.

Results: Approximately 90% of patients were eligible for oral anticoagulant (OAC) therapy. Overall use of OACs increased from 38% in 2010 to 45% in 2014; use of antiplatelet therapy decreased from 36 to 25%. Approximately 14% of eligible patients remained untreated.

Conclusion: Although an improvement in OAC prescription was observed post-DOACs launch, treatment patterns in Italy suggest that a proportion of patients with NVAF are still undertreated or do not receive appropriate therapy.

Keywords: OAC prescription; antithrombotic treatment patterns; direct oral anticoagulants; nonvalvular atrial fibrillation; real-world data.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

J-B Briere and K Bowrin are employees of Bayer AG. Manuscript development was supported by funding from Bayer. The other authors have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editorial assistance was utilized in the production of this manuscript with funding from Bayer AG.

Figures

<b>Figure 1.</b>
Figure 1.. Treatment patterns in 2010 and 2014 in patients eligible for oral anticoagulants – CHA2DS2-VASc score ≥2.
DOAC: Direct oral anticoagulant; Other anticoag: Other anticoagulant treatment; VKA: Vitamin K antagonist.
<b>Figure 2.</b>
Figure 2.. Antithrombotic use and treatment changes among patients with nonvalvular atrial fibrillation eligible for oral anticoagulants as per European Society of Cardiology guidelines during the 1-year follow-up in the pre- and post-direct oral anticoagulant cohorts.
(A) Antithrombotic use and (B) details of antithrombotic treatment changes among patients with nonvalvular atrial fibrillation eligible for oral anticoagulants as per European Society of Cardiology guidelines during the 1-year follow-up in the pre- and post-direct oral anticoagulant cohorts. DOAC: Direct oral anticoagulant; Other anticoag: Other anticoagulant treatment; VKA: Vitamin K antagonist.
See this image and copyright information in PMC

References

    1. Zoni-Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study) Am. J. Cardiol. 2013;111(5):705–711. - PubMed
    1. Ermini G, Perrone V, Veronesi C, Degli Esposti L, Di Pasquale G. Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study. Vasc. Health Risk Manag. 2017;13:239–246. - PMC - PubMed
    1. Ceornodolea AD, Bal R, Severens JL. Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries. Stroke Res. Treat. 2017;2017:8593207. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Atrial fibrillation fact sheet. 2017. www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm
    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–2962. - PubMed

Publication types

LinkOut - more resources